Education
About Us
Working with TipRanks
Follow Us
PainChek Ltd (AU:PCK)
ASX:PCK
PCK Stock Chart & Stats
AU$0.29
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.29
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.17 - AU$1.05
Previous CloseN/A
Volume838.67K
Average Volume (3M)3.56M
Market Cap
AU$34.49M
Enterprise ValueAU$29.70M
Total Cash (Recent Filing)AU$4.78M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding209,007,310
10 Day Avg. Volume1,466,878
30 Day Avg. Volume3,559,149
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)-70.25
Price to Sales (P/S)23.25
P/FCF Ratio-11.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth AccelerationConsistent double-digit revenue growth indicates improving product-market fit and adoption across care providers. For a subscription-based digital health platform, sustained top-line expansion supports scale, recurring revenue growth, and the ability to leverage fixed R&D and sales costs over more customers.
Improving Gross MarginRising gross margins signal improving unit economics — likely from higher software licensing penetration, lower per-user costs, or pricing gains. Improved margins are durable as usage scales in software platforms, increasing the path to sustainable profitability if operating expenses are managed.
No Debt On Balance SheetAbsence of debt reduces default and interest burdens, giving strategic flexibility for growth investments or funding rounds. For a cash-burning SaaS health company, no leverage is a durable risk-mitigation factor that eases near-term liquidity stress and preserves operating cash flow allocation choices.
Bears Say
Persistent Cash BurnSustained large negative operating and free cash flows indicate the business is not self-funding and will need external capital. Repeated burn pressures liquidity, risks dilution or onerous financing, and constrains investments in sales or product development critical to long-term scale.
Deep Negative MarginsExtremely large negative net and operating margins show current revenue is far insufficient to cover operating structure. This structural unprofitability undermines sustainable free cash generation and means the firm must materially improve margins or scale revenues to reach viable profitability.
Negative Shareholders' EquityA shift to negative equity reflects accumulated losses and erodes the capital cushion for creditors and investors. This durable balance-sheet deterioration can limit financing options, raise cost of capital, and constrain long-term strategic flexibility unless profitability or equity is restored.
PainChek Ltd News
PCK FAQ
What was PainChek Ltd’s price range in the past 12 months?
PainChek Ltd lowest share price was AU$0.17 and its highest was AU$1.05 in the past 12 months.
What is PainChek Ltd’s market cap?
PainChek Ltd’s market cap is AU$34.49M.
When is PainChek Ltd’s upcoming earnings report date?
PainChek Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 165 days.
How were PainChek Ltd’s earnings last quarter?
PainChek Ltd released its earnings results on Feb 27, 2026. The company reported -AU$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.023.
Is PainChek Ltd overvalued?
According to Wall Street analysts PainChek Ltd’s price is currently Overvalued.
Does PainChek Ltd pay dividends?
PainChek Ltd does not currently pay dividends.
What is PainChek Ltd’s EPS estimate?
PainChek Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PainChek Ltd have?
PainChek Ltd has 209,007,310 shares outstanding.
What happened to PainChek Ltd’s price movement after its last earnings report?
PainChek Ltd reported an EPS of -AU$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.556%.
Which hedge fund is a major shareholder of PainChek Ltd?
Currently, no hedge funds are holding shares in AU:PCK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PainChek Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:PCK Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$60.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.03%
12-Months-Change
Fundamentals
Return on Equity
-8647.54%
Trailing 12-Months
Asset Growth
-48.60%
Trailing 12-Months
Company Description
PainChek Ltd
PainChek Limited develops and commercializes mobile medical device applications that provides pain assessment for individuals. The company offers PainChek, which uses camera in smartphones and tablets to capture video that is analyzed in real time using facial recognition software to indicate the presence of the pain. It serves patients suffering with dementia. The company was formerly known as ePAT Technologies Ltd and changed its name to PainChek Limited in January 2018. PainChek Limited is based in Sydney, Australia.
Technical Analysis
Mach7 Technologies
―
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
―
Alcidion Group Limited
―
Options Prices
Currently, No data available
---